Test to treat

Press Releases


Department of Public Health announces COVID-19 treatments available at testing sites to treat across Connecticut


CONTACT: Chris Boyle, Director of Communications

(860) 706-9654 – christopher.boyle@ct.gov

HARTFORD, Conn. — More than 40 “Test to Treat” sites are open across Connecticut, providing an important way for individuals to quickly access free treatment for COVID-19, according to the Connecticut Department of Public Health.

Thanks to the new national launch Test to treat initiative, people can get tested and – if they test positive and the treatments are right for them – fill a prescription from a healthcare provider, all in one place. Connecticut currently has these Test to Treat sites, located in select federally licensed pharmacies, urgent care centers, and health centers.

“For COVID-19 treatments to work, they must start early, within five days of the onset of your symptoms,” said DPH Commissioner Manisha Juthani, MD. “The Test to Treat initiative provides eligible patients with faster and easier access to potentially life-saving treatments.”

A website locator is now available to make it easier to find Test to Treat locations. Those who may have difficulty accessing the internet or need additional help locating a Test to Treat site can call 1-800-232-0233 (ATS 1-888-720-7489) for help in English, Spanish, and over 150 other languages, 8 a.m. to midnight ET, seven days a week. Disability Access and Information Line (DIAL) is also available to specifically help people with disabilities access services. For assistance, call 1-888-677-1199Monday-Friday 9am-8pm ET or via email DIAL@usaginganddisability.org.

Other places to get COVID-19 therapeutics

People can also be tested and treated by their own health care providers who can appropriately prescribe these oral antiviral pills. If prescribed by their healthcare provider, patients can fill a prescription at a federally licensed health center or at many retail pharmacies located throughout the state.

Each week, DPH receives regular allocations of COVID-19 therapies from the federal government. While these therapeutics remain in limited supply, DPH is working with healthcare providers and pharmacies to get these therapeutics to high-risk communities to ensure health equity.

To have public places that have received shipments of COVID-19 therapeutic products purchased by the U.S. government under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authority, please visit COVID-19 Therapeutic Locator (arcgis.com).

COVID-19 therapies can be used to prevent or treat eligible outpatients who have tested positive for COVID-19 and have mild to moderate symptoms. Prevention and early treatment of eligible patients can help improve patient outcomes, reduce healthcare facility stress, and even save lives.

These therapies differ in their efficacy, their route of administration, their risk profile and the populations for which they are authorized. Some also have significant contraindications and drug interactions. For more information, please visit the HHS Side-by-Side Overview of Authorized Outpatient Therapies for the Treatment of Mild to Moderate COVID-19.

For more information, please visit DPH’s COVID-19 Therapeutics website at COVID 19 Therapeutics (ct.gov).

Questions from providers and the public about COVID therapies can be directed to COVIDmeds.DPH@ct.gov.


Edward K. Thompson